Live Breaking News & Updates on Steadymed Ltd

Stay updated with breaking news from Steadymed ltd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K

NOTICE OF ANNUAL GENERAL MEETING

OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024

- AND -

MANAGEMENT INFORMATION CIRCULAR

. ....

University Of Dayton , United States , New Jersey , United Kingdom , New York , Princeton University , Sanofi Pasteur , Angela Holtham , Laurel Hill , Broadridge Quickvote , Deborahm Brown , Thomasc Heineman , Jamest Parsons , Aptose Biosciences , Matthewc Coffey , Amyg Levin , Matt Coffey , Berndr Seizinger , Bernd Seizinger , Bristol Myers Squibb , Patricia Andrews , Allison Hagerman , Wayne Pisano , Revolo Biotherapeutics , Jonathan Rigby , Michael Bennett ,

Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 9, 2023 - Form 6-K

NOTICE OF ANNUAL GENERAL MEETING

OF SHAREHOLDERS TO BE HELD ON MAY 9, 2023

- AND -

MANAGEMENT INFORMATION CIRCULAR

. | April 6, 2023 ....

United States , United Kingdom , New York , New Jersey , Princeton University , University Of Dayton , Leonard Kruimer , Matt Coffey , Bristol Myers Squibb , Thomasc Heineman , Jonathan Rigby , Allison Hagerman , Deborah Brown , Michael Bennett , Wayne Pisano , Deborahm Brown , Jamest Parsons , Aptose Biosciences , James Parsons , Matthewc Coffey , Bernd Seizinger , Revolo Biotherapeutics , Sanofi Pasteur , Angela Holtham , Berndr Seizinger , Management Of The Corporation ,

Oncolytics Biotech Inc.: Oncolytics Biotech Appoints Jonathan Rigby to its Board of Directors

Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB ....

United Kingdom , Matt Coffey , Jonathan Rigby , Jon Patton , Revolo Biotherapeutics , Timothy Mccarthy , Oncolytics Biotech Inc , United Therapeutics Corporation , Company Contact , Sheffield University , Zogenix Inc , Portsmouth University , Steadymed Ltd , Securities Exchange , Bristol Myers Squibb , Honors In Biological Sciences , Group Chief Executive Officer , Chief Executive Officer , Oncolytics Biotech , Oncolytic Board , United Therapeutics , Profile Therapeutics , Phillips Medical , Immunomolecular Therapeutics Boards , Biological Sciences , Securities Exchange Act ,

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

/PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Jonathan Rigby to its Board of Directors. "Jonathan has. ....

United Kingdom , Matt Coffey , Jonathan Rigby , Jon Patton , Revolo Biotherapeutics , Timothy Mccarthy , Oncolytics Biotech Inc , United Therapeutics Corporation , Company Contact , Sheffield University , Zogenix Inc , Portsmouth University , Steadymed Ltd , Oncolytics Biotech , Securities Exchange , Bristol Myers Squibb , Honors In Biological Sciences , Group Chief Executive Officer , Chief Executive Officer , Oncolytic Board , United Therapeutics , Profile Therapeutics , Phillips Medical , Immunomolecular Therapeutics Boards , Biological Sciences , Securities Exchange Act ,

Stipulation of Partial Judgment In Favor of Liquidia Filed In Hatch-Waxman Litigation

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ....

United States , Jason Adair , Liquidia Technologies Inc , York Heart Association , United Therapeutics Corporation , Drug Administration , Us District Court , Steadymed Ltd , Liquidia Corporation , Corporate Development , Hatch Waxman Act , Chief Executive Officer , Patent Trial , Appeal Board , Orange Book , New Drug Application , Prepare Treprostinil , Active Ingredient , New York Heart Association , Functional Class , Dry Powder Inhalation , Liquidia Technologies , Private Securities Litigation Reform Act , Globe Newswire , United Therapeutics Corp ,